酸枣仁皂苷A生物吸收的细胞学机制
详细信息    本馆镜像全文|  推荐本文 |  |   获取CNKI官网全文
摘要
目的
     通过试验观察人结肠癌细胞(the human colon carcinoma cell line,Caco-2)对酸枣仁皂苷A(Jujuboside A,JuA)摄取与转运过程,探明JuA在Caco-2细胞模型中的吸收特性,为深入研究JuA的药理学作用机制提供理论和试验依据。
     方法
     ① 建立并采用高效液相(High Pressure Liquid Chromatography,HPLC)方法检测JuA的浓度,评价Caco-2细胞吸收JuA的能力。
     ② 建立与评估Caco-2细胞模型,由于Caco-2细胞来源和培养条件差异,不同克隆Caco-2细胞之间增殖和生化特性不尽相同。即使在相同的培养条件下,细胞模型的某些生物物理和生化特征也会有一定的差异,所以各实验间的数据只具参考价值,不可直接套用。因此本实验室在Caco-2细胞模型建立之初对一些参数如光镜检查,电镜检查,跨上皮细胞电阻(transepithelial elect rical resistance,TEER),葡聚糖的通透性等指标进行测定,以确证单层Caco-2细胞模型的特异性。
     ③ 通过MTT法了解不同浓度的JuA对Caco-2细胞的毒性作用。
     ④ 绘制培养时间-细胞药物摄取量曲线,考察时间对Caco-2细胞摄取JuA的影响,并同时考察pH、浓度及温度对Caco-2细胞摄取JuA的影响。
     ⑤ 研究P-糖蛋白(P-glycoprotein,P-gp)抑制剂维拉帕米(Verapamil,Ver)及代谢抑制剂叠氮化钠(Sodium azide),2,4-二硝基酚(2,4-Dinitrophenol)对Caco-2细胞摄取JuA的影响,探讨JuA的吸收机制。
     ⑥ Caco-2细胞在Transwell上培养21天后,分别在顶侧(Apical,AP)和基底侧(Basolateral,BL)加入100μg·ml~(-1)的JuA,通过表观通透系数(Apparent permeability coefficient,Papp)的测定来探导JuA的转运机制。
OBJECTIVE
    To explore the absorption and transport mechanism of JuA in human
    intestinal by uptake and transport experiment in Caco-2 cell model and to offer the theoretics and experimental gist for lucubrate of pharmacological mechanism of JuA.
    METHODS
    ① Establishing the HPLC analyse method for JuA.
    ② The establishment and evaluation of Caco-2 cell model:Because of the difference between source and culture condition, different Caco-2 cell line have different characteristic in multiplication and biochemistry. Even in the same culture condition, there are some difference between biology and bilchemistry, So the data of different laboratory only have reference worthiness, and they can not be apply mechanically. Thus we had determine some parameter such as normal microscope, transmission electron microscope, transepithelial elect rical resistance,the permeability of dextran before the establishment of Caco-2 cell model in order to insure the reliability of monolayer .
    ③ acquainting the toxicity of JuA on Caco-2 cell by MTT method.
    ④Seeing about the time, pH,concentration course for the uptake of JuA by Caco-2 cell, we protract the curve of culture time-uptake by Caco-2 cell. We also observe different pH、 concentration and temperature course for the uptake of JuA by Caco-2 cell.
    ⑤To study Verapamil, the inhibitor of P-glycoprotein (P-gp), Sodium azide and 2,4-Dinitrophenol ,the inhibitor of metabolism,course for the uptake of JuA by Caco-2 cell, and explore the absorption mechanism of JuA.
    ⑥Caco-2 were seeded on Transwell and grew for about 21 days for using,
引文
[1] 丘明明,黎有新.酸枣仁研究近况.中医药研究,1995;(4):60—2
    [2] 彭智聪,朱建军..酸枣仁化学成分及药理研究进展.时珍国医国药,2001;12(1):86—7
    [3] 陈昕,周秋丽,王本祥.人参皂甙Rb1在大鼠肠内菌代谢物吸收入血成分的研究.药学学报,1999;34(7):481-3
    [4] 王毅,刘铁汉,王巍,等.人参皂苷Rg1的肠内菌代谢及其代谢产物吸收入血的研究.药学学报,2000;35(4):284-8
    [5] 王毅,刘铁汉,王巍,等.肠内菌群对人参皂苷Rgl的代谢转化作用的研究.中国中药杂志,2001;26(3):188-90
    [6] 王金辉,李铣.拟人参皂苷F11在大鼠体内的药物代谢研究.药学学报,2001;36(6):427-31
    [7] 上官棣华,刘国诠.人参成分的代谢研究进展.中草药,1999;30(11):865-70
    [8] 谢海棠,王广基,赵小辰,等.Caco-2细胞对人参皂苷Rg3的摄取及代谢研究.中国临床药理学与治疗学,2004,9(3):257-260
    [9] 马吉胜,周秋丽,费晓方,等.真菌对人参皂苷Rb1及人参二醇系皂苷的代谢作用.药学学报,2001,36(8):603-605
    [10] 沈凯,王景田.药物肠吸收实验研究方法进展.中国新药杂志,2003;12(12):988—91
    [11] 梁桂贤,刘谦民.药物肠吸收研究方法近况.国外医药,1998;19(4):251-2
    [12] 胡晓渝,姚彤炜,曾苏.Caco-2细胞系及其在药物吸收、代谢中的应用.中国现代应用药学杂志,2002;19(2):88-90
    [13] 蒋学华,贾运涛,袁媛,等.Caco-2细胞模型在口服药物吸收过程研究中的应用.中国药学杂志,2002;37(5):325-7
    [14] 关溯,陈孝,黄民.Caco-2细胞模型——药物吸收研究的有效“工具”.中国药理学通报,2004;20(6):609-14
    [15] 杨海涛,王广基.Caco-2单层细胞模型及其在药学中的应用.药学学报,2000;35(10):797—800
    [16] 张亚.皂苷类成分的生物样品测定方法5年来研究近况.医学信息,2005;18(6):677-9
    [17] 司徒镇强,吴军正.细胞培养.世界图书出版社,2004;301-2
    [18] Ranaldi G, Consalvo R, Sambuy Y, et al. Permeability characteristics of parental and clonal human intestinal caco-2 cell lines differentiated in serumsupple mented and serumfree media. Toxicology In Vitro, 2003; 17: 761-7.
    [19] 王琰,李正荣,潘飞燕,等.纳米脂质体包裹胰岛素经Caco-2细胞转运的研究.中国药理学通报,2005;21(1):78-81
    [20] 王多宁,赵雁武,田芙蓉.考马斯亮兰微盘比色法测定蛋白质含量.第四军医大学学报,2001;22(6):528-9
    [21] 李娟,张耀庭,曾伟,等.应用考马斯亮兰法测定总蛋白含量.中国生物制品学杂志,2000;13(1).118-20
    [22] 司徒镇强,吴军正.细胞培养.世界图书出版社,2004;250—2
    [23] 李正荣,王琰,潘飞燕,等.Caco-2细胞模型建立及其在纳米脂质体包裹胰岛素体外吸收研究中的应用.南京师大学报,2004;27(3):88—91
    [24] 李玉娟,梁鑫淼,肖红斌,等.大鼠上次性灌服酸枣仁提取物后棘苷的药代动力学研究.药学学报,2003;38(6):448—50
    [25] 李会军,李萍.高效液相色谱法蒸发光散射检测器测定酸枣仁中酸枣仁皂苷A及B的含量.药物分析杂志,2000;20(2):82—4
    [26] 李素云,李蔚.HPLC同时测定保健食品中酸枣仁皂甙A和人参皂甙Rbl方法的研究.中国卫生检验杂志,2004;14(1):51-2
    [27] HPLC法测定安神胶囊中酸枣仁皂苷A的含量.中草药,2004;35(3):277-9
    [28] RP-HPLC法测定酸枣仁中黄酮碳苷的含量.中草药,2001;32(12):1079-80
    [29] 孙桂鸿,施群,刘春新,等.酸枣仁汤单煎与合煎提取物中菝葜皂甙元含量的比较研究.湖北中医杂志,2000;22(11):48-9
    [30] 牟永平,吴刚,周立社,等.Caco-2细胞模型在药物研究中的应用.中国药理学通报,2005;21(5):536-9
    [31] 刘莱,王东凯,高斐.Caco-2细胞模型在药物开发中的应用.西北药学杂志,2004;19(2):88—90
    [32] 山莽挺,王广基.Caco-2模型在肽类药物吸收特性研究中的应用.药学进展,2001;25(2):96—9
    [33] 刘志伟, 陈秉衡.Caco-2细胞单层模型及其在毒理学中的应用. 卫生研究,2004;33(6):756-9
    [34] Artursson P, Palm K, Luthman K.Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev, 2001; 46: 27-43
    [35] Sha XY, Fang XL. Transport characteristics of 9-Nitrocamptothecin in the human intestinal cell line and everted gut sacs. Int J Pharm, 2004; 272: 161-71
    [36] Gan LS, Thakker D. Application of the Caco-2 model in the design and development of orally active drugs:elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv Drug Deliv Rev, 1997; 23: 77-98
    [37] Artursson P, Karlsson J. Correlation between oral drug absorption in human and apparent drug permeability coefficients in human intestinal epithelial(Caco-2)cells. Biochem Biophy Res Commun, 199; 175: 880-5
    [38] Yamashita S, Furubayashi T, Kataoka M, et al. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci, 2000; 10: 195-204
    [39] Gharat L, Taneja R, Natthida W, et al. Targeted drug delivery system6:intracellular bioreductive activation, uptake and transport of an anticancer drug delivery system across intestinal Caco-2 cell monolayers. Int J Pharm, 2001; 219:1-10
    [40] Artursson P, Karlsson J. Correlation between oral drug absortion in human and apparent drug permeability coefficients in human intestinal epithelial(Caco-2)cells.Bilchem Biophys Res Communications,1991;175(3):880-5.
    [41] Karksson J, Ungell AL, Artursson P. Effect of an oral rehydration solution on paracellular drug transport in intestinal epithelial cells and tissues:Assessment of charge and tissue selectivity. Pharm Res, 1994; 11: 235-48
    [42] Tanaka Y, Taki Y, Sakane T, et al. Characterization of drug transport though tight-junctional pathway in Caco-2 monolayers:comparison with isolated rat jejunum and colon. Pharm Res, 1995; 12: 523-8
    [1] 彭任辉,肖午阳.植物皂苷与中药.中华实用中西医杂志,2001,1(14):2202.
    [2] 樊永蓉;廖庆文.中草药中皂苷类有效成分药理作用研究现状.湖南中医药导报,2003,9(11):52-53.
    [3] 徐先祥,夏伦祝,高家荣.中药皂苷类物质抗氧化作用研究进展.中国中医药科技,2004,11(2):126-128.
    [4] 赵铁华,邓淑华,宋鸿儒.人参皂甙Rg1协同诱生LAK细胞的抗瘤活性.中国肿瘤临床,1994,21(1):48-49.
    [5] 徐安平,崔若兰.柴胡皂甙d对实验性膜性肾炎疗效及作用机理研究.肾脏病与透析肾移植杂志,1995,4(3):215-217.
    [6] 陈旭,郑惠民,由振东,等.β-七叶皂苷钠对大鼠脑出血后脑水肿及脑内精氨酸加压素含量的影响.第二军医大学学报,2001,22(12):1142-1144.
    [7] 封洲燕,郭殿武,苏松,等.酸枣仁皂甙A镇静和抗惊厥作用试验.浙江大学学报,2002,31(2):103-106.
    [8] 余伯阳,殷霞,荣祖元.短葶山麦冬皂甙C的药理活性研究.中国药科大学学报,1994,25(5):286-288.
    [9] 金有豫,耿朝晖.知母皂甙D对心肌缺血/复灌性损伤的保护作用的分析.首都医学院学报,1994,15(2):138-139.
    [10] 李伯刚,周正质.治疗心血管疾病新药地奥心血康的化学.新药与临床,1994,13(2): 75-77.
    [11] 刘明杰,林琳,王钊.肠道细菌对天然药物代谢的研究进展Ⅰ.中国现代应用药学杂志,2001,18(2):90-91.
    [12] 孙艳,李雪驼,殷素兰.肠道内微生态环境对中草药体内代谢的影响.中草药,2001,32(4):375-377.
    [13] 左风,严梅桢,周钟鸣.肠道菌群对中药有效成分代谢作用的研究进展.中国中药杂志,2002,27(8):568-571.
    [14] 杨秀伟.中药实验医学研究中的关键基础科学科学问题——从肠内细菌生物转化确定中药有效和有毒化学成分.中西医结合学报,2005,3(2):154-159.
    [15] 康白.微生态学.大连:大连出版社,1988:95
    [16] 韩国柱.药物在肠道的代谢及其对药物作用的影响.药学通报,1985,20(5):294.
    [17] 谷黎红,李铣,陈英杰,等.大丁草中抗菌活性成分的研究:人肠道微生物对大丁甙及其类似物的代谢产物.药学学报,1988,23(7):511-513.
    [18] 马海英,刘玉春,宋建丽.地奥心血康肠道吸收作用的研究及其机制的初步探讨.辽宁药物与临床,2003,6(4):175—177.
    [19] Kida H, Akao T, Meselhy MR, et al. Metabolism and pharmacokinetic of oral administration saikosaponin B1 in conventional, germ-free and Eubacterium sp. A-44-infected gnoyobiote rats. Biol Pharm Bull, 1998, 21(6): 588-593.
    [20] Akao T, Kobashi K, Aburada M. Enzymic studies on the animal and intestinal bacterial metabolism of geniposide. Biol Pharm Bull, 1994, 17(12): 1573-1579.
    [21] Krishnamuty HG. Identification of products produced by the anaerobic degradation of rutin and related flavonnids by butrivibrio sp. C3. Can J Microbiol, 1970, 16(8): 759-767.
    [22] Carter J H, Mclafferty MA, Goldman P. Role of the gastrointestinal microflora in amygdalin-induced cyanide toxicity. Biochem Pharmacol, 1980, 29(3): 301-304.
    [23] Kansmuller S, Mohn GR. On the disteibution of genotoxin factors in various organs of mice treated with cycasin. Chem Biol Interact, 1986, 58(1): 109-113.
    [24] Kawata Y, Ma CM, Meselhy MR, et al. Conversion of aconitine to lipoaconitine by human intestinal bacteria and their antinociceptive defects in mice. J Tradit Med, 1999, 16(1): 15-17.
    [25] 赵锐,邢增涛,李向高,等.肠内细菌对天然药物的化学修饰.吉林农业大学学报,1998,20(2):103-110.
    [26] Jang-Shim YIM, Young-Suk KIM, Sang-Kwan MOON, et al. Metabolic Activities of Ginsenoside Rb1, Baicalin, Glycyrrhizin and Genipwside to Their Bioactive Compounds by Human Intestinal. Biol. Pharm Bull, 2004, 27(10): 1580-1583.
    [27] Akao T, Yoshino T, Kobashi K, et al. Evaluation of salicin as an antipyretic prodrug that does not cause gastric injury. Planta Med. 2002, 68(8): 714-718.
    [28] 刘明杰,林琳,王钊.肠道细菌对天然药物代谢的研究进展Ⅱ.中国现代应用药学杂志,2001,18(4):257-260.
    [29] Akao Taiko. Effects of pH on metabolism of glycyrrhizin, glycyrrhetic acid and glycyrrhetic acid monoglucuronide by collected human intestinal flora. Bio Pharm Bull, 2001, 24(10): 1108-1112.
    [30] 严梅桢:人肠道菌对柴胡皂苷的代谢.国外医学中医中药分册,2001,23(3):156-158.
    [31] Sun-Young, Eun-Ah Bae, Jong Hwan-Sung, et al. Purification and characterization of ginsenoside Rb1-metabolizingβ-glucosidase from Fusobacterium K-60, a human intestinal anaerobic bacterium. Biosci. Biotechnol. Biochem, 2001, 65(5): 1163-1169.
    [32] 陈英杰.20(S)-人参皂苷Rg2的代谢产物研究.沈阳药学院学报,1987,4(3):202-204.
    [33] Karikura M, Miyase T, Taniyama T, et al. Studies on absorption, distribution, excretion and metabolism of ginseng saponins. Ⅵ. The decomposition products of ginsenoside Rb2 in the stomach of rats. Chem Pharm Bull, 1991, 39(2): 400-405.
    [34] Karikura M, Miyase T, Taniyama T, et al. Studies on absorption, distribution, excretion and metabolism of ginseng saponins. Ⅶ. Comparison of the decomposition modes of ginsenoside Rb1 and Rb2 in the digestive tract of rats. Chem Pharm Bull, 1991, 39(9): 2357-2367.
    [35] 沈岚,徐德生,冯怡,等.大鼠肠内菌对麦冬皂苷D′代谢的研究.中国中药杂志,2005,30(8):618—620.
    [36] Kyo ich i K, Teruak i A. Relation of intestinal bacteria to pharmaco logical effects of glyco sides. Bioscience Microf lora, 1997, 16(1): 1-3.
    [37] Akao T, Kanaoka M, Kobashi K. Appearance of compound k, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration measurement of compound k by enzymy immunoassay. Biol Pharm Bull.1998, 21(3): 245-251.
    [38] 陈昕,周秋丽,王本祥.人参皂甙Rb1在大鼠肠内菌代谢物吸收入血成分的研究.药学学报,1999,34(7):481-483.
    [39] Wakabayashi C, Hasegawa H, Murata J. In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration. Oncol Res, 1997, 9(8): 411-422.
    [40] 王毅,蒋艳,王本祥,等.人参皂苷Rg1及其肠内菌代谢产物Rh1对小鼠免疫细胞功能的影响.药学学报,2002,37(12):927-429.
    [41] Hasegawa H, Lee KS, Nagaoka T, et al. Pharmacokinetics of ginsenoside deglycosylated by intestinal bacteria and its transformation to biologically active fatty acid esters. Biol Pharm Bull, 2000, 23(3): 298-305.
    [42] Hasegawa H, Uchiyama M. Antimetastatic afficacy of orally administered ginsenoside Rb1 in dependence on intestinal bacterial hydrolyzing potential and significance of treatment with an active bacterial metabolite. Planta Med, 1998, 64(8): 696-706.
    [43] 马海英,周秋丽,王本祥.黄山药总皂苷肠内菌代谢及代谢产物吸收的研究.中国药房,2002,13(4):204-205.
    [44] Nose M, Ito M, Kamimura K, et al. A comparison of antihepatotoxic activity between glycyrrhizin and glycyrrhinic acid. Planta Med, 1993, 49(2): 136-142.
    [45] 杨秀伟,赵静,崔景荣,等.七叶树皂苷-Ia的人肠内细菌生物转化产物及其抗肿瘤活性研究.北京大学学报,2004,36(1):31-35.
    [46] 陈继永,吴立军,滕厚雷,刘珂.肠内菌群对七叶皂苷体外代谢转化产物的研究.中草药,2003,34(11):970-973.
    [47] 杨秀伟,郝美荣,服部征雄.中药成分代谢分析.中国医药科技出版社,2003:41-42.
    [48] Kim DH, Jang IS, Lee SW. Bacteroides J-37, a human intestinal bacterium, produces alpha-glucuronidase. Biol Pharm Bull. 1997, 20(8): 834-837.
    [49] Kim DH, Lee SW, Han MJ. Biotransformation of glycyrrhizin to 18beta-Glycyrrhetinic acid-3-O-beta-D-glucuronide by strep-tococcus LJ-22, a Human Intestinal Bacterium. Biol Pharm Bull, 1999, 22(3): 320-322.
    [50] Akao Taiko. Influence of various bile acids on the metabolism of glycyrrhizin and glycyrrhetic acid by ruminococcus sp. PO1-3 of human intestinal bacteria. Biol Pharm Bull, 1999, 22(8): 787-793.
    [51] Akao Taiko. Hasty effect on the metabolism of glycyrrhizin by eubacterium sp. GLH with rum inococcus sp. PO 1-3 and Clostridium innocuum ES24-06 of Human Intestinal bacteria. Biol Pharm Bull, 2000, 23(1): 6-11.
    [52] Akao Taiko. Effects of glycyrrhizin and glycyrrhetic acid on the growth, glycyrrhizin beta-D-glucuronidase and 3beta-hydroxysteroid dehydrogenase of human intestinal bacteria. Biol Pharm Bull, 2000., 23(1): 104-107.
    [53] 赵雷,陈昕,陈晓.肠内菌对人参皂甙Rb1的代谢特点.长春中医学报,2004,20(1):45-49.
    [54] Akao T, Kida H, Kanaoka M, et al. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol, 1998, 50(10): 1155-1160.
    [55] Kida H, Akao T, Meselhy M R, et al. Enzymes responsible for the metabolism of saikosaponins from eubacterium sp. A-44, a human intestinal anaerobe. Biol Pharm Bull, 1997, 20(12): 1274-1278.
    [56] Kida H, Akao T, Meselhy M R, et al. Metabolism and pharmacokinetic of oral administration saikosaponin b1 in conventional, germ-free and Eubacteri-um sp. A-44-infected gnotobiote rats. Biol Pharm Bull, 1998, 21(6): 588-593.
    [57] 毛羽,鱼红闪,金凤燮.黄芪皂苷糖苷酶产生菌的筛选及其酶反应条件.大连工业学院学报,2005,24(1):19-21.
    [58] 马吉胜,周秋丽,费晓方,等.真菌对人参皂苷Rb1及人参二醇系皂苷的代谢作用.药学学报,2001,36(8):603-605.
    [59] Akao T, Hattori M, et al. 3β-hydroxysteroid dehydrogenase of ruminococcus sp.from human intestinal bacteria. J Biochem, 1986, 99: 1425-1431.
    [60] Wang Zhao, Kuro saki Yuji, Nakayama Taiji, et al. Mechanism of gastrointestinal absorption of glycyrrhizin in rats.Biol Pharm Bull, 1994, 17(10): 1399-1403.
    [61] Timo Korjamo, Paavo Honkakoski, Marjo-Riitta Toppinen, et al. Absorption properties and P-glycoprotein activity of modified caco-2 cell line. Pharm Scien, 2005, 26: 266-279.
    [62] 李昊,孙建国,谢海棠,等.大鼠肠管外翻模型对人参皂苷Rg1吸收机制的研究.中国临床药理学与治疗学,2004,9(5):510-513.
    [63] 谢海棠,王广基,赵小辰等.Caco-2细胞对人参皂苷Rg3的摄取及代谢研究.中国临床药理学与治疗学,2004,9(3):257-260.
    [64] 马海英,周秋丽,王继彦,等.大鼠肠内菌对黄山药总皂苷代谢及代谢产物鉴定.中国中药杂志,2002,27(9):680-683.
    [65] 王毅,刘铁汉,王巍,等.肠内菌群对人参皂苷Rg1的代谢转化作用的研究.中国中药杂志,2001,26(3):188-190.
    [66] Akao T, Hayashi T, Kobashi K, et al.Intestinal bacterial hydrolysis is indispensable to absorption of 18β-glycyrrhetic acid after oral administration of glycyrrhizin in rats. J Pharm Pharmacol, 1994, 46(2): 135-139.
    [67] 张东明,宫濑敏男,野口博司,等.黄花倒水莲皂甙Reinioside C在大鼠体内代谢产物的鉴定.高等学校化学学报,2002,23(1):63-67.
    [68] 王毅,刘铁汉,王巍,等.人参皂苷Rg1的肠内菌代谢及其代谢产物吸收入血的研究.药学学报,2,000,35(4):284-288.
    [69] 胡晓渝,姚彤炜,曾苏.Caco-2细胞系及其在药物吸收、代谢中的应用.中国现代应用药学杂志,2002,19(2):88-90.
    [70] 郭涛.Caco-2细胞模型在药物动力学研究中的应用.中国药师,2003,6(12):774-776.
    [71] 刘莱,王东凯,高斐.Caco-2细胞模型在药物开发中的应用.西北药学杂志,2004,19(2):88-90.